Publications

Found 47 results

Filters: Author is Seaman, Michael S [Clear All Filters]

2018

Cohen YZ, Lorenzi JCC, Seaman MS, Nogueira L, Schoofs T, Krassnig L, Butler A, Millard K, Fitzsimons T, Daniell X et al.. 2018. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.. J Virol. 92(5)

2017

Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al.. 2017. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med. 23(2):185-191.

Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X et al.. 2017. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.. Sci Transl Med. 9(406)

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al.. 2017. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373):pii:eaa12144.

Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al.. 2017. Early antibody therapy can induce long-lasting immunity to SHIV.. Nature. 543(7646):559-563.

Horwitz JA, Bar-On Y, Lu C-L, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS et al.. 2017. Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.. Cell. 170(4):637-648.

Julg B, Liu P-T, Wagh K, Fischer WM, Abbink P, Mercado NB, Whitney JB, Nkolola JP, McMahan K, Tartaglia LJ et al.. 2017. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.. Sci Transl Med. 9(408)

Julg B, Pegu A, Abbink P, Liu J, Brinkman A, Molloy K, Mojta S, Chandrashekar A, Callow K, Wang K et al.. 2017. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.. J Virol. 91(16):pii:e00498-17.

2016

Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. 2016. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.. Cell. 165(7):1609-20.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu C-L, Lorenzi JCC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T et al.. 2016. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.. Nature.

Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JCC, Parrish EH, Learn GH et al.. 2016. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.. Science. 352(6288):997-1001.

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB et al.. 2016. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.. Nat Commun. 7:10618.

2015

Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC et al.. 2015. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.. Nature. 519(7541):87-91.

Ranasinghe S, Soghoian DZ, Lindqvist M, Ghebremichael M, Donaghey F, Carrington M, Seaman MS, Kaufmann DE, Walker BD, Porichis F. 2015. HIV-1 antibody neutralization breadth is associated with enhanced HIV-specific CD4+ T cell responses.. J Virol.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al.. 2015. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science.

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L et al.. 2015. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.. Cell. 161(7):1505-15.

McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW et al.. 2015. Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.. PLoS Pathog. 11(8):e1005110.

Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, West AP, Bjorkman PJ. 2015. Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1.. Cell. 160(3):433-46.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A et al.. 2015. A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.. PLoS Pathog. 11(10):e1005238.

Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF et al.. 2015. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.. Nature. 522(7557):487-91.

2014

Scharf L, Scheid JF, Lee J H, West AP, Chen C, Gao H, Gnanapragasam PNP, Mares R, Seaman MS, Ward AB et al.. 2014. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.. Cell Rep. 7(3):785-95.

Halper-Stromberg A, Lu C-L, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U et al.. 2014. Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice.. Cell.

Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. 2014. Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity.. Cell. 158(6):1243-53.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee J H, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang C-H et al.. 2014. Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers.. Immunity. 40(5):657-68.

Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR et al.. 2014. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.. J Exp Med. 211(12):2361-72.

Pages